CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection
The strong CD8+ T-cell-mediated HIV-1-suppressive capacity found in a minority of HIV-infected patients in chronic infection is associated with spontaneous control of viremia. However, it is still unclear whether such capacities were also present earlier in the CD8+ T cells from non controller patie...
Saved in:
Published in | PloS one Vol. 8; no. 3; p. e59767 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
29.03.2013
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The strong CD8+ T-cell-mediated HIV-1-suppressive capacity found in a minority of HIV-infected patients in chronic infection is associated with spontaneous control of viremia. However, it is still unclear whether such capacities were also present earlier in the CD8+ T cells from non controller patients and then lost as a consequence of uncontrolled viral replication. We studied 50 patients with primary HIV-1-infection to determine whether strong CD8+ T-cell-mediated HIV suppression is more often observed at that time. Despite high frequencies of polyfunctional HIV-specific CD8+ T-cells and a strong CD4+ T-helper response, CD8+ T-cells from 48 patients lacked strong HIV-suppressive capacities ex vivo. This indicates that the superior HIV-suppressive capacity of CD8+ T-cells from HIV controllers is not a general characteristic of the HIV-specific CD8+ T cell response in primary HIV infection. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 PMCID: PMC3612088 Competing Interests: The OPTIPRIM clinical trial was funded by the ANRS (French National Agency for Research on AIDS and Viral Hepatitis). However, ANRS received financial support from MSD, Janssen, ViiV Healthcare and Gilead to complement funding concerning this trial. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. Membership of the ANRS 147 OPTIPRIM clinical trial is provided in Text S1. Critical reviewing of manuscript: CL IG AC PV GN LM CR GP AV AS-C. Conceived and designed the experiments: AC CR GP AV AS-C. Performed the experiments: CL IG PV. Analyzed the data: CL IG LM GP AV AS-C. Contributed reagents/materials/analysis tools: GN. Wrote the paper: CL AS-C. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0059767 |